Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Share:
Related PRGO
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
Benzinga's Top #PreMarket Losers
Will Clinical Trial Firm Icon Pass This Market Test? (Investor's Business Daily)
Related IPXL
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
5 Biotechs Leerink Analysts Are Watching

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News

 

Related Articles (IPXL + PRGO)

View Comments and Join the Discussion!

Get Benzinga's Newsletters